Loading
A phase 3 trial of PM8002, Gemcitabine, Carboplatin and Eribulin in triple-negative breast cancer, run by BioNTech SE, now recruiting.
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer is a phase 3 interventional study registered as NCT07173751 by BioNTech SE, with 558 participants planned, started 2025-10-30 and due to reach its primary completion in 2029-12. Interventions recorded: Pumitamig, Nab-paclitaxel/Paclitaxel, Gemcitabine, Carboplatin, Eribulin and Matching placebo.
Shares Eribulin, BioNTech, Bristol Myers Squibb, Gemcitabine and the tag pipeline.
Shares PM8002, BioNTech, Triple-negative breast cancer (TNBC) and the tag pipeline.
Shares PM8002, BioNTech, Bristol Myers Squibb and the tag pipeline.